Cargando…
Pharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trials
Conventional synthetic disease-modifying anti-rheumatic drugs, including methotrexate, may not be tolerated by all patients with rheumatoid arthritis (RA), and limited international data for etanercept (ETN) monotherapy are available. The aim of this review was to summarize the clinical program for...
Autores principales: | Takeuchi, Tsutomu, Miyasaka, Nobuyuki, Kawai, Shinichi, Sugiyama, Naonobu, Yuasa, Hirotoshi, Yamashita, Noriaki, Sugiyama, Noriko, Wagerle, Lorin Craig, Vlahos, Bonnie, Wajdula, Joseph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445012/ https://www.ncbi.nlm.nih.gov/pubmed/24842477 http://dx.doi.org/10.3109/14397595.2014.914014 |
Ejemplares similares
-
Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
por: Yamanaka, Hisashi, et al.
Publicado: (2016) -
Guidelines for the proper use of etanercept in Japan
por: Miyasaka, Nobuyuki, et al.
Publicado: (2006) -
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
por: Nishimoto, Norihiro, et al.
Publicado: (2008) -
Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study
por: Hashimoto, Jun, et al.
Publicado: (2010) -
Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study
por: Maksymowych, Walter P, et al.
Publicado: (2016)